title: A phase II study of doxifluridine and docetaxel combination chemotherapy for advanced or recurrent gastric cancer.
abstract: BACKGROUND
  The aim of this study was to establish the efficacy and safety of doxifluridine and docetaxel for patients with advanced or recurrent gastric cancer.
  
  
  METHODS
  The regimen consisted of oral administration of doxifluridine 533 mg/m(2) per day on days 1-14 and an intravenous infusion of docetaxel 50 mg/m(2) on day 8. The primary endpoint was the overall response rate. The secondary endpoints were overall survival, progression-free survival, and toxicities.
  
  
  RESULTS
  Between June 2004 and December 2006, a total of 40 eligible patients were enrolled in this study. Seven of them showed a partial response, with an overall response rate of 17.5%. The response rate was 18.8% in 32 patients with refractory tumors. The median progression-free survival time and the median overall survival time were 2.6 months and 12.7 months, respectively, in all 40 patients; and 2.6 months and 14.0 months, respectively, in the 32 patients with refractory tumors. Grade 3/4 hematological toxicity included neutropenia in 52.5%, leukocytopenia in 17.5%, and febrile neutropenia in 7.5%. Grade 3 or more nonhematological toxicities were infrequent.
  
  
  CONCLUSIONS
  The combination chemotherapy of doxifluridine and docetaxel was well tolerated and relatively effective when used as a second-line chemotherapy for advanced or recurrent gastric cancer.
authors.affiliation: Department of Gastrointestinal Surgery, Kanagawa Cancer Center, 1-1-2 Nakao, Asahi-ku, Yokohama 241-0815, Japan.
authors.forename: Takaki
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Akira
authors.initials: A
authors.lastname: Tsuburaya
authors.forename: Ken
authors.initials: K
authors.lastname: Shimada
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sato
authors.forename: Makoto
authors.initials: M
authors.lastname: Takahashi
authors.forename: Wasaburo
authors.initials: W
authors.lastname: Koizumi
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Yoshizawa
authors.forename: Kazuhito
authors.initials: K
authors.lastname: Nabeshima
authors.forename: Masayuki
authors.initials: M
authors.lastname: Kimura
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Hataya
authors.forename: Osamu
authors.initials: O
authors.lastname: Kobayashi
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D000077143:Docetaxel; D005260:Female; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D043823:Taxoids; D005467:Floxuridine; D000077143:Docetaxel; C025034:doxifluridine